💼 Polyplus will use its e-Zyvec® technology to design tailor-made plasmids for manufacturing.
💡 The teams will work together to optimize critical process parameters and upstream raw materials.
💪 The collaboration will also promote the exchange of knowledge to advance cell and gene therapy manufacturing.
Introduction:
Polyplus, a part of Sartorius, has announced a collaboration with MarkHerz, a Korean cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), to develop new CGT efficiency standards. The collaboration aims to decrease the cost and increase the quality per dose of therapeutic products by improving process efficiency.
- Polyplus and MarkHerz will work together to optimize CGT manufacturing processes.
- The collaboration will leverage Polyplus’s e-Zyvec® technology to design tailor-made plasmids for manufacturing.
- The teams will focus on improving yield and quality by optimizing critical upstream raw materials and process parameters.
- The collaboration will also involve building and sharing local knowledge to advance CGT manufacturing.
Conclusion:
The collaboration between Polyplus and MarkHerz aims to advance cell and gene therapy process standards by optimizing manufacturing processes and improving yield and quality. By leveraging Polyplus’s expertise and products, along with MarkHerz’s manufacturing capabilities, the teams hope to decrease the cost and increase the quality per dose of therapeutic products. This collaboration will contribute to the advancement of cell and gene therapy manufacturing and promote the exchange of knowledge and expertise in the field.
